Citadel Advisors
DBTX

Citadel Advisors’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Citadel Advisors’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,787,311
Closed -$3.66M – 15983
2022
Q4 		$3.66M Sell
1,787,311
-21,675
-1% -$66K ﹤0.01% 4407
2022
Q3 		$6.26M Buy
1,808,986
+16,678
+0.9% +$75.9K 0.01% 3514
2022
Q2 		$7.55M Buy
1,792,308
+18,617
+1% +$44K 0.01% 3070
2022
Q1 		$5.39M Buy
1,773,691
+130
+0% +$498 0.01% 4026
2021
Q4 		$8.25M Sell
1,773,561
-4,098
-0.2% -$28.2K 0.01% 3385
2021
Q3 		$13.7M Buy
1,777,659
+3,828
+0.2% +$29.2K 0.02% 2568
2021
Q2 		$14.9M Sell
1,773,831
-4,565
-0.3% -$40.3K 0.02% 2479
2021
Q1 		$20.2M Buy
+1,778,396
New +$27.9M 0.02% 1949

Other funds holding DBTX

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return